Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with its headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included over 25 therapies. Key products with approved indications in the U.S. include: In HIV, Biktarvy® is a once-daily oral single-tablet regimen for HIV-1 infection, combining bictegravir, emtricitabine (FTC), and tenofovir alafenamide (TAF). Descovy® is an oral formulation used with other antiretroviral agents for HIV-1 infection and is also FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in certain patients. Descovy is a fixed-dose combination of FTC and TAF. Genvoya® is a once-daily oral single-tablet regimen for HIV-1 infection, combining elvitegravir, cobicistat, FTC, and TAF. Odefsey® is a once-daily oral formulation for the treatment of HIV-1 infection in certain patients.